CDK12 is hyperactivated and a synthetic-lethal target in BRAF-mutated melanoma
oleh: Thibault Houles, Geneviève Lavoie, Sami Nourreddine, Winnie Cheung, Éric Vaillancourt-Jean, Célia M. Guérin, Mathieu Bouttier, Benoit Grondin, Sichun Lin, Marc K. Saba-El-Leil, Stephane Angers, Sylvain Meloche, Philippe P. Roux
| Format: | Article |
|---|---|
| Diterbitkan: | Nature Portfolio 2022-10-01 |
Deskripsi
In patients with melanoma, increased RAS/mitogen-activated protein kinase (MAPK) pathway activity is known to drive chemotherapy resistance. Here, the authors identify CDK12 as a downstream effector of the RAS/MAPK pathway and therapeutic target which mediates chemotherapy resistance through increased expression of DNA repair associated genes.